Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?

For a patient with triple-negative metaplastic breast cancer and microinvasive residual disease (ypT1miN0)following neoadjuvant therapy, the decision to use adjuvant capecitabine is nuanced and not definitively addressed in current guidelines or trials.

1. General TNBC with Residual Disease:
   • Multiple...

Short answer: yes. Although we have data from CREATE-X, data from GEICAM were negative. Data from FinXX and SYSUCC001, however, were positive. TNBC still carries a high risk of recurrence even with small-volume residual disease. Retrospective and prospective data suggest that chemotherapy is particu...